Neutrophils can shape adaptive immunity, however their role in vaccine-induced 17 protection against infections in vivo remains unclear. Here, we tested their role in the 18 clinically relevant polysaccharide conjugate vaccine against Streptococcus pneumoniae 19 (pneumococcus). We antibody depleted neutrophils during vaccination, allowed them to 20 recover, and four weeks later challenged mice with pneumococci. We found that while 21 isotype-treated vaccinated controls were protected against an otherwise lethal infection in 22 naïve mice, full protection was lost upon neutrophil depletion. Compared to vaccinated 23 controls, neutrophil-depleted mice had higher lung bacterial burdens, increased incidence 24 of bacteremia and lower survival rates. Sera from neutrophil-depleted mice had less anti-25 pneumococcal IgG2c and IgG3, were less efficient at inducing opsonophagocytic killing 26 of bacteria by neutrophils in vitro and worse at protecting naïve mice against pneumococcal 27 pneumonia. In summary, neutrophils are required during vaccination for optimal host 28 protection, which has important implications for future vaccine design against 29 pneumococci and other pathogens. 30 31
years old lack mature B cells, they fail to produce T-independent Abs [7] . Therefore, the 48 pneumococcal conjugate vaccine (PCV), was introduced for use in children. PCV 49 contains polysaccharides linked to a carrier protein that triggers a T-dependent Ab 50 response [4] . PCV has had great efficacy in children and is currently recommended for 51 use in immunocompromised adults and elderly individuals with underlying conditions 52
[6]. As PCV is recommended for adults with compromised immunity including B and T 53 cell responses [4] , it is important to elucidate novel players in vaccines that could be 54 potential targets to boost protection. 55
Abs against capsular polysaccharides following vaccination bind to S. 56 pneumoniae and protect the host against infection [4] . The functionality of Abs is 57 determined by their antigen affinity. Affinity to antigens is mediated via the variable 58 regions which make up the Fab or antigen binding portions and is optimized by somatic 59 hypermutation (SHM) [8] . The Fc or constant region of Ab, which determines their class, 60 also shapes their function, with the different classes of Abs having distinct immune 61 polysaccharides are typically produced by marginal zone B cells in the spleen [9] . In 63 contrast, T cell-dependent Ab production occurs in germinal centers, where a specialized 64 subset of CD4+ T-follicular helper cells (TFH) [10] induce B cells to undergo class-65 switch recombination and SHM resulting in Abs with improved function [11] . PCV 66 significantly boosts class switching to IgG as compared to PPSV [12] and further induces 67 TFH cells which correlate with enhanced Ab function [13] . 68
Polymorphonuclear leukocytes (PMNs) or neutrophils, play a crucial role in 69 innate immunity to infections [14] . It is now appreciated that PMNs can also regulate 70 adaptive immunity. PMNs can directly induce Ab production by B cells [11] . In the 71 spleen, a subset of PMNs termed B helper neutrophils was described to produce APRIL, 72 BAFF and IL-21 [9] that triggered Ab production by marginal-zone B cells [9, 15 ]. This 73 was described for T-independent antigens including bacterial polysaccharides [9] . PMNs 74 may also affect T cell dependent Ab responses [15] , however, that is less established. 75
PMNs are thought to both activate and suppress T cells [16] . PMNs produce a repertoire 76 of chemokines that recruit T-cells and also produce cytokines that drive T-cell subset 77 differentiation [16] . PMN-derived products can prime T cells to more efficiently respond 78 to antigens [17] . PMNs also activate T cells via recruiting and activating antigen 79 presenting cells [18] or acting as antigen presenting cells themselves [16, [19] [20] [21] [22] [23] Sera was collected from all mice prior to immunization, as well as two and four weeks 119 post immunization and saved at -80C for subsequent assays. 120
Neutrophil Depletion 121
Mice were treated intra-peritoneally (i.p.) with 50 g of the Ly6G-depleting antibody IA8 122 or isotype IgG control (BioXCell) following the timeline in Fig 1A. 123
Adoptive Transfer of Sera 124
Five weeks following immunization, vaccinated, vaccinated PMN-depleted and naïve 125 mice were euthanized and blood harvested via cardiac puncture. Sera was obtained from 126 the blood, pooled for each group and transferred i.p (250l) into naïve recipients. 127
Recipients were then infected one hour later [31] . 128
Animal Infections 129
Mice were intra-tracheally (i.t.) challenged with 107 colony-forming units (CFU) of WT 130 monitored daily over one week for bacteremia as well as clinical signs of disease 132 including weight loss, activity level, posture and breathing and blindly scored from 0 133 (healthy) to 21 (severely sick). Twenty-four hours post infection, another set of mice 134 were euthanized and lung and blood were assessed for CFU. 135
Antibody ELISA 136
Sera Ab levels were measured by ELISA as previously described [31] . Nunc maxisorp® 137 plates were coated overnight at 4oC with type 4 Pneumococcal Polysaccharide (ATCC®) 138 at 2ug/well. Plates were washed and blocked for 2 hours. The sera were preabsorbed with 139 a pneumococcal cell wall polysaccharide mixture (CWP-multi from Cederlane) to 140 neutralize non-capsular Abs and then added to the plate. After a 3h incubation and 141 washing, pneumococcal-specific Abs were detected using HRP-conjugated goat anti-142 mouse IgM (Invitrogen), IgG (Millipore Sigma), IgG1, IgG2b, IgG2c or, IgG3 (Southern 143 Biotech) followed by TMB substrate (Thermo Scientific™) and readings at OD650 using a 144 BioTek reader. Kinetic ELISAs were performed with readings every minute for 10 145 minutes. Ab units were calculated as percentages of a control hyperimmune serum 146 included in each ELISA. Hyperimmune sera was pooled from mice that were intra-147 nasally inoculated with S. pneumoniae TIGR4 over four weeks as previously described 148
[31], immunized with PCV at week 4 and injected i.p. with heat-killed bacteria at week 5. 149
Myeloperoxidase (MPO) ELISA 150
MPO levels were measured in lung homogenates using the Mouse Myeloperoxidase 151 ELISA kit from InvitrogenTM as per manufacturer's instructions. 152
Isolation of PMNs 153
1119 and Histopaque 1077 (Sigma) as previously described [28] . PMNs were 155 resuspended in Hanks' Balanced Salt Solution (HBSS without Ca2+ and Mg2+) 156 supplemented with 0.1% gelatin and used in subsequent experiments. Purity was 157 confirmed by flowcytometry and the isolated cells were 85-90% Ly6G+. 158
Opsonophagocytic Killing Assay (OPH) 159
The ability of PMNs to kill pneumococci was assessed as previously described [28] . 160
Briefly, 1x105 PMNs were infected with 1x103 bacteria pre-opsonized with 3% mouse 161 sera in 100 l reaction volumes of HBSS/0.1% gelatin (with Ca2+ and Mg2+) and rotated 162 at 37C for 40 minutes. The reactions were stopped on ice and plated for CFU. The 163 percent of bacteria killed was calculated using no PMN controls. 164
Flow Cytometry 165
One day following the last PMN depletion, mice were euthanized and blood, vaccine 166 draining popliteal lymph nodes and spleen were harvested. Single-cell suspensions of 167 splenocytes and lymph nodes were prepared by mashing the organs through sterile mesh 168 screens using the plunger of a 3-ml syringe. Red blood cells were lysed with a hypotonic 169 buffer and the cells surface stained for Ly6G (IA8 or RB6, Biolegend), CD11b (M1/70, 170
Invitrogen,), CD11c (N418, BD Bioscience), F4/80 (BM8, BD Bioscience) and Ly6C 171 (AL-21. BD Bioscience) in the presence of Fc-block (BD Bioscience). Live cells were 172 identified using a dead cell stain kit (Life Technologies). Fluorescence intensities were 173 measured on a BD Fortessa and at least 20,000 events were analyzed using FlowJo. 174
Statistical Analysis 175
were determined by Fisher's exact test, One-way ANOVA followed by Dunnet's test or 177
Student's t-test as appropriate. Survival analyses were performed using the log-rank 178 (Mantel-Cox) test. p values less than 0.05 were considered significant. To test if PMNs were required for protection at the time of vaccination with PCV, 184
we used the anti-Ly6G Ab IA8 to deplete PMNs or isotype controls one day prior to and 185 every two days throughout the first week following vaccination (timeline- Fig 1A) . One 186 day after the final treatment, we verified depletion in the blood and found ~99% reduction 187 in the number of circulating PMNs ( Fig S1A) . As splenic PMNs have a role in Ab 188 production [9, 15], we also examined PMN numbers in the spleen. We found that upon 189 vaccination there was a ~2-fold increase in splenic PMNs ( Fig S1B) and that treatment 190 with depleting Abs resulted in ~98% depletion of those cells ( Fig S1B) . We also verified 191 that Ab treatment was specific to PMNs and did not result in any changes in the number of 192 circulating and splenic monocytes, dendritic cells or macrophages ( Fig S2) . 193
Four weeks following vaccination, we challenged mice i. and that is covered by PCV. We then monitored the disease course and as expected found 200 that while all naïve mice rapidly succumbed to infection, 100% of vaccinated mice 201 survived ( Fig 1B) . However, unlike vaccinated controls, full protection was lost in PMN-202 depleted mice (Fig 1) . The majority of PMN-depleted mice displayed severe clinical signs 203 of disease where 77.8% got sick as compared to only 12.5% of vaccinated controls (Fig  204   1C ). PMN-depleted mice had between 10-100-fold higher pulmonary bacterial numbers 205 ( Fig 2A) and systemic spread ( Fig 2B) into the circulation, culminating in significantly 206 reduced survival ( Fig 1B) as compared to vaccinated controls. This reduced protection in 207 PMN-depleted mice was not due to the continued absence of PMNs at the time of 208 challenge, as we verified that there was no difference in PMN presence in the lungs as 209 measured by MPO levels following infection ( Fig S1C) . Rather, our findings suggest that 210
PMNs are required at the time of vaccination with PCV for full protection against 211 subsequent pneumococcal infection. 212 213 PMNs are required for optimal antibody isotype switching in response to PCV 214 immunization 215
Next, we wanted to explore the mechanisms by which PMNs contributed to 216 vaccine-induced protection. We first examined Ab production and as expected observed 217 isotype switching to IgG by week 4 post vaccination in our control group (Fig 3) . We 218 found that PMN depletion did not alter IgM or total IgG levels against capsular 219 polysaccharide type 4 ( Fig 3A and B) or heat-killed S. pneumoniae (not shown). 220
However, when we examined IgG subtypes, we found that depletion of PMNs during 221 vaccination resulted in slightly reduced levels of IgG2b ( Fig 4A) and significantly lower 222 levels of IgG2c ( Fig 4B) and IgG3 ( Fig 4C) at week 4 post vaccination. Interestingly, 223
IgG1 levels ( Fig 4D) were slightly, but not significantly elevated in PMN depleted group 224 as compared to vaccinated controls. These data suggest that PMNs play a role in class 225 switching to certain IgG subtypes. we observed a 30-fold increase in the amount of IgG bound to bacteria when sera from 233 vaccinated mice were used ( Fig 5A) . As expected, in immune sera, the bound IgG was 234 specific to capsular polysaccharides as very little IgG bound to acapsular bacteria (cps 235 S. pneumoniae). Interestingly, we observed a significant decrease in the amount of IgG 236 bound to S. pneumoniae opsonized with sera from PMN-depleted mice as compared sera 237 from vaccinated controls ( Fig 5A) . 238
We next compared the opsonic capacity of Abs by comparing the ability of sera to 239 induce opsonophagocytic (OPH) killing of S. pneumoniae by primary PMNs isolated 240 from naive mice. We found sera from vaccinated controls significantly boosted bacterial 241 killing by PMNs where 60% of the bacterial input were killed by PMNs in the presence 242 of immune sera as compared to ~10% with naïve sera (Fig 5B) . Strikingly, sera from 243 PMN-depleted mice failed to induce opsonophagocytic killing of S. pneumoniae by 244 complement pathway and directly kill bacteria [8] but we detected no differences in the 246 ability of sera alone from any of the mouse groups to kill pneumococci ( Fig S3) . 247
Given the difference in the in vitro function we observed, we finally tested the 248 protective activity of Abs generated upon vaccination in the absence of PMNs. Naive 249 young mice were injected i.p. with five-week sera from either vaccinated controls, naïve 250 mock-immunized mice or our PMN depleted vaccinated group. Mice were then 251 challenged i.t. with S. pneumoniae TIGR4 one hour following sera transfer. We found 252 that while all of the mice receiving naïve sera succumbed to infection, all of the mice 253 receiving sera from vaccinated controls survived the challenge ( Fig 5C) . In contrast, only 254 half of the mice receiving sera from the PMN depleted vaccinated group survived (Fig  255   5C ). These data indicate that Abs produced during vaccination in the absence of PMNs 256
are not sufficient to provide protection against subsequent pneumococcal infection. PMNs are clearly required for optimal Ab responses, however whether they are 297 acting on T cells remains to be determined. 298
A key finding here is that PMNs are required for the production of IgG3 but not IgG1 subtypes. The IgG subtype produced in response to PCV 312 varies in humans based on age, with IgG2 being the predominant response in 313 adults [12, 43] . We found that PMNs were crucial for the ability of Abs to elicit 314 opsonophagocytic killing of bacteria by primary immune cells. This is in line with 315 data from humans where although the opsonophagocytic activity of IgG subtypes vary 316 based on bacterial serotype, IgG2 was reported to have the highest activity while IgG1 317 had the lowest activity against serotype 4 pneumococci [44]. We also found that PMNs 318
were required for production of Abs that protect against infection. This could be mediated 319 by IgG2 [44] or IgG3 which was shown to be protective in mice against pneumococcal 320 
